UZ Leuven

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Source

• Not yet recruiting

  A study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus

  2025-524595-37-00· Phase 1· Source

• Not yet recruiting

  Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement

  NCT07877298· Source

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Source

• Not yet recruiting

  The CORE Platform Trial

  NCT07892976· Source

• Not yet recruiting

  Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

  NCT07738887· Phase 2· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Source

• Not yet recruiting

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· Phase 2· Source

• Not yet recruiting

  Assessment of self-perceived stress and repetitive behaviors after six weeks of daily intranasal oxytocin administration versus placebo: a randomised, multicentre, parallel group pragmatic trial in 210 men and women with autism

  2025-524797-42-00· Phase 3· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Source

• Not yet recruiting

  A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

  NCT07919405· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· Source

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Source

• Recruiting

  Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression

  2025-524641-27-00· Phase 3· Source

• Recruiting

  STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma

  NCT07863258· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Source

• Recruiting

  This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

  NCT07587658· Phase 4· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Source

• Not yet recruiting

  Prospective diagnostic performance of PET/CT using the novel fibroblast imaging tracer [18F]-AlF-FAPI-74 versus power doppler ultrasound in psoriasis patients with arthralgia: early detection of psoriatic arthritis

  2026-526942-29-00· Phase 2/3· Source

• Recruiting

  Prospective Trial of [18F]AlF-FAPI-74 for PET Imaging of Fibroblast Activation Protein in Patients With Endometriosis

  NCT07876648· Phase 2· Source

• Recruiting

  Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07441200· Phase 2· Source

• Recruiting

  ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole

  2025-524995-53-00· Phase 4· Source

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

  NCT07817875· Phase 3· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Source

• Recruiting

  Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

  NCT07753148· Phase 1· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Source

• Not yet recruiting

  Rehabilitation Through Individualized Support and Exercise

  NCT07857096· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Source

• Recruiting

  A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

  NCT07625215· Phase 2· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

  NCT07587242· Phase 3· Source

• Recruiting

  Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation

  NCT07405671· Phase 4· Source

• Recruiting

  A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

  NCT07630714· Phase 2· Source

• Recruiting

  A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum

  2026-526016-36-00· Phase 4· Source

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Source

• Recruiting

  A clinical trial of MK-8210 in healthy participants (MK-8210-001)

  2026-527022-13-00· Phase 1· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  2025-525105-20-00· Phase 1/2· Source

• Recruiting

  A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  NCT07566052· Phase 3· Source

• Not yet recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)

  NCT07760818· Phase 2· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

  NCT07626411· Phase 3· Source

• Not yet recruiting

  Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

  NCT07682129· Phase 2· Source

• Not yet recruiting

  Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiotherapy

  2025-523575-36-00· Phase 2· Source

• Recruiting

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping

  2025-523087-20-00· Phase 3· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07481981· Phase 3· Source

• Recruiting

  Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)

  NCT07227805· Source

• Not yet recruiting

  The HYCORE1 Trial: Hybrid Revascularization Versus Coronary Artery Bypass Grafting

  NCT05504031· Source

• Recruiting

  A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  2026-525234-39-00· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer35 recruiting
• Childhood cancers34 recruiting
• Ovarian cancer26 recruiting
• Crohn's disease24 recruiting
• Colorectal cancer23 recruiting
• Metastatic breast cancer19 recruiting
• Ulcerative colitis16 recruiting
• Pancreatic cancer15 recruiting
• Endometrial cancer13 recruiting
• Gastric and esophageal cancer13 recruiting
• High blood pressure12 recruiting
• Prostate cancer12 recruiting
• Acute myeloid leukemia11 recruiting
• ALS (motor neurone disease)10 recruiting
• Chronic lymphocytic leukaemia10 recruiting
• Duchenne muscular dystrophy10 recruiting
• Obesity10 recruiting
• Coronary artery disease9 recruiting
• Parkinson disease9 recruiting
• Head and neck cancer8 recruiting
• Liver and biliary tract cancer8 recruiting
• Melanoma8 recruiting
• Multiple myeloma8 recruiting
• Alzheimer disease7 recruiting
• Atrial fibrillation7 recruiting
• Bladder cancer7 recruiting
• Heart failure7 recruiting
• Idiopathic pulmonary fibrosis7 recruiting
• Pulmonary arterial hypertension7 recruiting
• Rheumatoid arthritis7 recruiting
• Stroke7 recruiting
• Lupus (SLE)6 recruiting
• Myelodysplastic syndromes6 recruiting
• Sarcoma6 recruiting
• Triple-negative breast cancer6 recruiting
• Acute lymphoblastic leukaemia5 recruiting
• COPD5 recruiting
• Psoriasis5 recruiting
• Type 1 diabetes5 recruiting
• Type 2 diabetes5 recruiting
• Amyloidosis4 recruiting
• Cervical cancer4 recruiting
• Glioblastoma4 recruiting
• Kidney cancer4 recruiting
• Lewy body dementia4 recruiting
• Myasthenia gravis4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Neuroendocrine tumours4 recruiting
• Ankylosing spondylitis3 recruiting
• Autism3 recruiting
• Chronic myeloid leukaemia3 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
• Cystic fibrosis3 recruiting
• Endometriosis3 recruiting
• Hodgkin lymphoma3 recruiting
• Polycystic kidney disease3 recruiting
• Psoriatic arthritis3 recruiting
• Sjögren's disease3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Chronic kidney disease2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Epilepsy2 recruiting
• Frontotemporal dementia2 recruiting
• Haemophilia2 recruiting
• Huntington's disease2 recruiting
• Neuroblastoma2 recruiting
• Pompe disease2 recruiting
• Primary biliary cholangitis2 recruiting
• Asthma1 recruiting
• Fabry disease1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Follicular lymphoma1 recruiting
• HIV1 recruiting
• IgA nephropathy1 recruiting
• Macular degeneration1 recruiting
• Multiple sclerosis1 recruiting
• Osteoporosis1 recruiting
• Schizophrenia1 recruiting
• Sickle cell disease1 recruiting
• Spinal muscular atrophy1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

  NCT06595563· Phase 2· Source

• Not yet recruiting

  HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before

  2025-524230-25-00· Phase 2· Source

• Completed

  A clinical trial of MK-1824 in healthy participants (MK-1824-001)

  2026-525748-14-00· Phase 1· Source

• Completed

  A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis

  NCT07222189· Phase 2· Source

• Completed

  A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC

  2025-522867-13-00· Phase 2· Source

• Completed

  An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489

  2025-521155-23-00· Phase 2· Source

• Completed

  A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations

  2025-521480-12-00· Phase 1· Source

• Recruiting

  Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

  NCT07048262· Phase 2· Source

• Recruiting

  A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

  2024-520201-39-00· Phase 2· Source

• Completed

  A Study With CIT-013 in RA Patients

  NCT06567470· Phase 2· Source

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis

  NCT06867094· Phase 2· Source

• Completed

  A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP

  2024-518364-12-00· Phase 2· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· Source

• Completed

  A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KRAS-G12D mutation, when given alone and with other cancer drugs

  NCT06599502· Phase 1/2· Source

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Source

• Completed

  A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis

  2023-507771-22-01· Phase 3· Source

• Active, not recruiting

  Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

  NCT06840483· Phase 2· Source

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Source

• Completed

  A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy

  2023-508998-85-00· Phase 1· Source

• Active, not recruiting

  Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

  NCT06632951· Phase 2· Source

• Active, not recruiting

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· Phase 2· Source

• Completed

  A clinical study of MK-2420 in healthy men (MK-2420-003)

  2024-518104-47-00· Phase 1· Source

• Completed

  Smart MDI Study (CIP343)

  NCT06645834· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· Source

• Completed

  A safety and efficacy study of ARGX-119 in adult patients with Amyotrophic Lateral Sclerosis (ALS) (reALiSe)

  NCT06441682· Phase 2· Source

• Active, not recruiting

  Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

  NCT06321601· Phase 3· Source

• Withdrawn

  3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Stents in NSTE/ACS

  NCT06409117· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Source

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Source

• Completed

  A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

  2023-508736-62-00· Phase 2· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Source

• Recruiting

  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Phase 3· Source

• Recruiting

  Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis

  2023-507539-40-00· Phase 2· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Source

• Active, not recruiting

  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

  NCT06456580· Phase 3· Source

• Completed

  Add-on Clioquinol in drug-resistant epilepsy: an exploratory study

  2024-511388-27-04· Phase 2· Source

• Active, not recruiting

  A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

  NCT06290128· Phase 3· Source

• Terminated

  To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

  NCT06488911· Phase 3· Source

• Completed

  Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction

  2023-506210-40-00· Phase 3· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Source

• Active, not recruiting

  Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

  NCT06359002· Phase 1· Source

• Completed

  Robotic Subretinal tPA Injection Study

  NCT06347107· Source

• Completed

  A Phase 1, Open-Label Study to Investigate the TARP-ɣ8 Receptor Occupancy of RAP-219 Using a TARP-γ8 PET Tracer in Healthy Adult Participants

  2024-512151-21-00· Phase 1· Source

• Completed

  A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphoma

  NCT06561425· Phase 1/2· Source

• Completed

  Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

  NCT06468527· Phase 2· Source

• Completed

  A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects with Cystic Fibrosis Aged 18 Years or Older (CHOICES)

  2022-500410-26-01· Phase 2· Source

• Recruiting

  Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

  NCT06414954· Phase 2· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· Phase 2· Source